A systematic review of rodent-borne orthohantaviruses: Discovery, epidemiology, evolution, pathogenicity, vaccines, and therapeutics
- 1Department of Microbiology, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
- 2Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Medical College, Fudan University, Shanghai, China
- 3Department of Microbiology, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China; Corresponding authors.
Abstract
Rodent-borne orthohantaviruses currently comprise 37 species and 69 strains according to the International Committee on Taxonomy of Viruses (ICTV; Feb 2026 release, MSL #41). Among these, six species are etiologic agents of hemorrhagic fever with renal syndrome (HFRS), and six others cause hantavirus pulmonary syndrome (HPS). In the absence of widely available specific therapeutics or licensed vaccines, the World Health Organization (WHO) has designated orthohantaviruses as priority pathogens with a high risk of precipitating a public health emergency of international concern. This narrative review systematically synthesizes seven decades of orthohantavirus research across six thematic sections, taxonomy and discovery history, epidemiological characteristics, viral biology and evolutionary dynamics, pathogenic mechanisms, and recent advances in vaccine development and therapeutic strategies. We highlight the discovery trajectories and epidemiological profiles of six representative Old World and New World orthohantaviruses. To elucidate host-virus interplay, we summarize the immune evasion tactics employed by orthohantaviruses and multifactorial basis underlying vascular hyperpermeability. Eight vaccine platforms are critically appraised, ranging from licensed inactivated vaccines to mRNA-based candidates that have demonstrated single-dose protection in lethal animal challenge models. Therapeutic approaches, including neutralizing antibodies, direct-acting antivirals, entry inhibitors, and host-targeted agents, are systematically evaluated. Finally, we identify critical knowledge gaps and priority research directions to inform accelerated development of effective medical countermeasures against this globally significant yet underrecognized viral threat.
Related
- AI-driven multi-omics biomarkers in precision breast cancer therapeutics: from discovery to clinical translation
- Clostridioides difficile infections and beyond: molecular epidemiology, One Health transmission chains, under-surveilled regions, and the next generation of diagnostics, therapeutics, and vaccines
- Antibody Discovery and Therapeutics in Spondyloarthritis: Recent Advances and Future Directions.
- Redefining drug discovery: AI-driven strategies for efficient cancer therapeutics.
- Epidemiology of pediatric intensive care unit admissions and mortality in low- and middle-income countries: a systematic review and meta-analysis
BibTeX
@article{ma2026systematic,
title = {{A systematic review of rodent-borne orthohantaviruses: Discovery, epidemiology, evolution, pathogenicity, vaccines, and therapeutics}},
author = {Hongwei Ma and Wei Ye and Yiwen Lv and Yingfeng Lei and Shibo Jiang and Fanglin Zhang and Zhikai Xu},
journal = {Current Research in Microbial Sciences},
year = {2026},
month = oct,
doi = {10.1016/j.crmicr.2026.100668},
url = {https://doi.org/10.1016/j.crmicr.2026.100668},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - A systematic review of rodent-borne orthohantaviruses: Discovery, epidemiology, evolution, pathogenicity, vaccines, and therapeutics
AU - Hongwei Ma
AU - Wei Ye
AU - Yiwen Lv
AU - Yingfeng Lei
AU - Shibo Jiang
AU - Fanglin Zhang
AU - Zhikai Xu
PY - 2026
DA - 2026/10/10
JO - Current Research in Microbial Sciences
DO - 10.1016/j.crmicr.2026.100668
UR - https://doi.org/10.1016/j.crmicr.2026.100668
AB - Rodent-borne orthohantaviruses currently comprise 37 species and 69 strains according to the International Committee on Taxonomy of Viruses (ICTV; Feb 2026 release, MSL #41). Among these, six species are etiologic agents of hemorrhagic fever with renal syndrome (HFRS), and six others cause hantavirus pulmonary syndrome (HPS). In the absence of widely available specific therapeutics or licensed vaccines, the World Health Organization (WHO) has designated orthohantaviruses as priority pathogens with a high risk of precipitating a public health emergency of international concern. This narrative review systematically synthesizes seven decades of orthohantavirus research across six thematic sections, taxonomy and discovery history, epidemiological characteristics, viral biology and evolutionary dynamics, pathogenic mechanisms, and recent advances in vaccine development and therapeutic strategies. We highlight the discovery trajectories and epidemiological profiles of six representative Old World and New World orthohantaviruses. To elucidate host-virus interplay, we summarize the immune evasion tactics employed by orthohantaviruses and multifactorial basis underlying vascular hyperpermeability. Eight vaccine platforms are critically appraised, ranging from licensed inactivated vaccines to mRNA-based candidates that have demonstrated single-dose protection in lethal animal challenge models. Therapeutic approaches, including neutralizing antibodies, direct-acting antivirals, entry inhibitors, and host-targeted agents, are systematically evaluated. Finally, we identify critical knowledge gaps and priority research directions to inform accelerated development of effective medical countermeasures against this globally significant yet underrecognized viral threat.
SN - 2666-5174
ER -